Table 3. Factors Associated With Severe or Very Severe Adverse Effects After COVID-19 Vaccination.
| Characteristica | OR (95%CI) | P value |
|---|---|---|
| Vaccine doseb | 2.59 (2.20-3.06) | <.001 |
| Brand | ||
| BNT162b2 | 1 [Reference] | NA |
| mRNA-1273 | 1.88 (1.63-2.17) | <.001 |
| JNJ-78436735 | 1.03 (0.67-1.58) | .89 |
| Self-reported COVID-19 before vaccine | 2.10 (1.63-2.70) | <.001 |
| Female sex (vs all others) | 1.68 (1.39-2.02) | <.001 |
| Age (per 10 y) | 0.89 (0.85-0.94) | <.001 |
| Influenza shot last year | 0.71 (0.58-0.87) | <.001 |
| Asthma | 0.77 (0.62-0.94) | .01 |
| Sleep apnea | 0.78 (0.63-0.95) | .01 |
| Subjective social status (per unit increase) | 0.95 (0.91-0.99) | .02 |
| Race | ||
| White | 1 [Reference] | NA |
| Asian | 1.23 (0.94-1.61) | .14 |
| Black or African American | 1.11 (0.65-1.91) | .71 |
| Multiracial | 1.07 (0.76-1.49) | .70 |
| Other | 1.25 (0.79-1.98) | .33 |
| Immunodeficiency | 0.75 (0.54-1.03) | .08 |
| Tobacco use | 1.07 (0.99-1.16) | .09 |
| Heart failure | 0.62 (0.34-1.11) | .11 |
| Hispanic ethnicity | 1.22 (0.94-1.59) | .14 |
| Pregnant at baseline | 1.40 (0.76-2.59) | .28 |
| Hypertension | 0.91 (0.76-1.09) | .29 |
| Atrial fibrillation | 0.86 (0.62-1.20) | .38 |
| Diabetes | 1.09 (0.80-1.49) | .59 |
| Anemia | 0.96 (0.77-1.18) | .67 |
| Stroke or TIA | 0.91 (0.58-1.43) | .68 |
| COPD | 0.93 (0.61-1.42) | .73 |
| Marijuana use | 0.99 (0.92-1.07) | .83 |
| Coronary heart disease | 0.95 (0.52-1.74) | .87 |
| HIV | 0.97 (0.41-2.30) | .95 |
| Myocardial infarction | 1.00 (0.67-1.48) | .99 |
Abbreviations: COPD, chronic obstructive pulmonary disease; NA, not applicable; OR, odds ratio; TIA, Transient Ischemic Attack.
a
All factors were entered into the multivariable logistic regression model simultaneously.
b
Adverse effects after 2 doses of BNT162b2 or mRNA-1273 or 1 dose of JNJ-78436735 compared with reference of adverse effects after 1 dose of BNT162b2 or mRNA-1273.